잠시만 기다려 주세요. 로딩중입니다.

The Therapeutic Effect of Cyclin-Dependent Kinase 4/6 Inhibitor on Relapsed Ectopic Male Breast Cancer

Journal of Breast Cancer 2020년 23권 5호 p.560 ~ 566
백동원, 박지영, 이수정, 채의수,
소속 상세정보
백동원 ( Baek Dong-Won ) - Kyungpook National University School of Medicine Kyungpook National University Chilgok Hospital Department of Oncology/Hematology
박지영 ( Park Jee-Young ) - Kyungpook National University School of Medicine Kyungpook National University Chilgok Hospital Department of Pathology
이수정 ( Lee Soo-Jung ) - Kyungpook National University School of Medicine Kyungpook National University Chilgok Hospital Department of Oncology/Hematology
채의수 ( Chae Yee-Soo ) - Kyungpook National University School of Medicine Kyungpook National University Chilgok Hospital Department of Oncology/Hematology

Abstract


Ectopic male breast cancer is very rare. Consequently, there is a lack of prospective clinical trials, and most recommendations for treatment are based on the experiences of clinicians and data from female breast cancer patients. The United States Food and Drug Administration has recently approved palbociclib combined with endocrine therapy for advanced male breast cancer because of the positive results of its use in metastatic female breast cancer. Therefore, it is worth considering cyclin-dependent kinase 4/6 inhibitors as alternatives to conventional chemotherapies for advanced male breast cancer patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative cancers. The present case report introduces the use of palbociclib plus letrozole as first-line therapy for an elderly male patient with relapsed ectopic breast cancer, notwithstanding the limitations of the current national health insurance policy.

키워드

Breast neoplasms; Male; Palbociclib

원문 및 링크아웃 정보

 

등재저널 정보